AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05041868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
Study NCT05433376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Intravascular Lithotripsy (IVL) System C2
Description: lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
Study NCT05601414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIO-Z
Description: a novel cuffless continuous BP wrist monitor
Study NCT05601414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finapres Nova
Description: a cuffless continuous BP monitor
Study NCT04690127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
Study NCT05774782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral flow diverter
Description: The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
Study NCT05441059 — intervention group
Intervention type: DRUG
Intervention: Mepolizumab 100 MG
Description: Treatment with mepolizumab for severe asthma
Study NCT04984655 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset
Description: All participants will go through the same intervention described above
Study NCT04973917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiratory support
Description: respirators for invasive mechanical ventilation
Study NCT05773924 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: triLift system
Description: To evaluate the efficacy of the triLift™ treatment
Study NCT05000749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-SG
Description: Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
Study NCT05000749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VHA treatment as usual
Description: VHA treatment as usual for Veterans at risk for suicide attempt
Study NCT05000749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VHA treatment as usual
Description: VHA treatment as usual for Veterans at risk for suicide attempt
Study NCT06358079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-infusion of unwashed shed blood
Description: Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
Study NCT05151939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist
Description: An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
Study NCT05151939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)
Description: Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
Study NCT06249308 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood sample will be collected
Study NCT05153655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local ischemic post-conditioning
Description: Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min.
Study NCT06323265 — intervention group
Intervention type: DRUG
Intervention: Adebrelimab + chemotherapy
Description: Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
Study NCT06323265 — intervention group
Intervention type: RADIATION
Intervention: ±chest radiotherapy
Description: Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
Study NCT05406310 — intervention group
Intervention type: DEVICE
Intervention: Ablation Index-guided ablation
Description: Radiofrequency catheter ablation guided by Ablation Index software.
Study NCT05406310 — intervention group
Intervention type: DEVICE
Intervention: High-power, short-duration ablation using QDOT Micro catheter
Description: Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
Study NCT05256433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-A
Description: IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
Study NCT05256433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group-B
Description: Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
Study NCT04360213 — intervention group
Intervention type: DEVICE
Intervention: Advanced multimodal wireless vital signs monitor
Description: Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
Study NCT06181123 — intervention group
Intervention type: OTHER
Intervention: Cardiorespiratory Assesments
Description: The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
Study NCT05460767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI363
Description: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
Study NCT05140044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Exercises - Smartphone Delivery
Description: 1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
Study NCT05140044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Exercises - Traditional Paper Delivery
Description: 1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
Study NCT05267379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Take blood samples
Description: Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
Study NCT05791786 — intervention group
Intervention type: OTHER
Intervention: Patient
Description: affected individuals diagnosed with AFE
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160mg (2 capsules) oral bid；
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/CD22 CAR-T
Description: Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine For Injection
Description: Azacitidine For Injection 100mg i.h. d1-d5;
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 300mg/m2 ivgtt d3-d5;
Study NCT05797948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300mg/m2 ivgtt d3-d5.
Study NCT05487859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets
Description: Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
Study NCT05688137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal drainage
Description: The patients with intervention will take an abdominal drainage.
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone 50mg Capsule
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone 100mg Capsule
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin matching Placebo
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin matching Placebo
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balcinrenone 50mg matching Placebo
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balcinrenone 50mg matching Placebo
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balcinrenone 100mg matching Placebo
Description: see arms
Study NCT05884866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balcinrenone 100mg matching Placebo
Description: see arms
Study NCT06466057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
Study NCT06466057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General mental health promotion
Description: A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
Study NCT05417009 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: trans-cutaneous auricular sensory stimulation
Description: Transcutaneous auricular sensory stimulation
Study NCT05417009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trans-cutaneous auricular sensory stimulation
Description: Transcutaneous auricular sensory stimulation
Study NCT05879796 — intervention group
Intervention type: DRUG
Intervention: cis-platinum
Description: chemotherapeutics
Study NCT05879796 — intervention group
Intervention type: RADIATION
Intervention: radiation
Description: External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks.
Study NCT05879796 — intervention group
Intervention type: DRUG
Intervention: Envafolimab Injection
Description: PD-L1 antibody
Study NCT05879796 — intervention group
Intervention type: DRUG
Intervention: Recombinant Human Endostatin Injection
Description: angiogenesis inhibitors
Study NCT03998852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) with [18F]-FDOPA
Description: Positron Emission Tomography (PET) with \[18F\]-FDOPA
Study NCT03998852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) with [18F]-FEOBV
Description: Positron Emission Tomography (PET) with \[18F\]-FEOBV
Study NCT03998852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonnance Imaging (MRI)
Description: MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
Study NCT03998852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
Study NCT04794049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
Study NCT04794049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Description: In control cohort, patients use the standard split-dose bowel preparation regimen,
Study NCT05762588 — intervention group
Intervention type: DEVICE
Intervention: Juggerknot with Broadband tape
Description: The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
Study NCT06176417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal ridge augmentation by decompression technique.
Description: Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
Study NCT06176417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal ridge augmentation by ridge splitting technique using piezosurgery.
Description: horizontal ridge augmentation was done using piezosurgery tips and bone expanders
Study NCT05854693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transCranial direct current stimulation
Description: The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
Study NCT05854693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The sham group consisted of 10 daily 20-min sessions of sham stimulation
Study NCT04817241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04817241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04817241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04817241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT04817241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study NCT04817241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT04817241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05368324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogFun-RV
Description: CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
Study NCT05368324 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CogFun-RV
Description: CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
Study NCT06313541 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT or LDRT
Description: Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.
Study NCT06313541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
Description: The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
Study NCT06313541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
Description: The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
Study NCT05961696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Subcutaneous (SQ or Sub-Q) injection under the skin
Study NCT06354881 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres
Description: TCD will be used to measure the cerebral blood flow in the middle and posterior cerebral arteries. This will be done at rest and during two sit-stand manoeuvres, whereby the participant will be asked to stand (from a seated position) and stay standing for 1 minute. The participant will then be given time to recover before repeating the manoeuvre. This will occur at the first visit and the follow-up visit 4 weeks after.